公开(公告)号：US20170342164A1

公开(公告)日：2017-11-30

申请号：US15617291

申请日：2017-06-08

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Bipulendu JENA ,  Sourindra MAITI

IPC分类号： C07K16/42 ,  C12N5/0783 ,  G01N33/566 ,  C07K14/705 ,  C07K16/28

CPC分类号： C07K16/4208 ,  C07K14/70503 ,  C07K14/70517 ,  C07K16/2803 ,  C07K16/4283 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/31 ,  C07K2319/33 ,  C12N5/0636 ,  C12N2510/00 ,  G01N33/566

摘要： Provided are monoclonal antibodies that detect CD19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.

公开(公告)号：US20160158285A1

公开(公告)日：2016-06-09

申请号：US14890977

申请日：2014-05-14

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K35/17 ,  C07K14/54

CPC分类号： A61K35/17 ,  C07K14/5443 ,  C07K14/7051 ,  Y02A50/411 ,  Y02A50/467

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

摘要翻译： 本发明涉及使用包含嵌合抗原受体（CAR）的修饰T细胞的免疫治疗方法和组合物。 在特定方面，CAR表达的T细胞使用电穿孔与基于转座子的整合系统一起产生，以产生需要最小离体扩增或可直接施用于患者疾病的CAR表达细胞群体（例如 ，癌症）治疗。

公开(公告)号：US20170044500A1

公开(公告)日：2017-02-16

申请号：US15306187

申请日：2015-04-24

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI

IPC分类号： C12N5/074 ,  A61K39/00 ,  G01N33/566 ,  C12N15/86 ,  C12N5/0789

CPC分类号： C12N5/0696 ,  A61K39/0011 ,  A61K2039/5158 ,  C12N5/0647 ,  C12N15/86 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2502/1114 ,  C12N2506/45 ,  C12N2510/00 ,  G01N33/566 ,  G01N2333/705 ,  G01N2333/7051

摘要： The application of induced pluripotent stem cells (iPSCs) to generate adoptive cell therapy products and usage of iPSCs for screening potential toxicity of immune receptors are described herein. In some aspects, iPSCs and cells differentiated therefrom are provide which do not express a HLA gene (e.g., HLA-A).

摘要翻译： 本文描述了诱导多能干细胞（iPSCs）在产生过继细胞治疗产品中的用途以及iPSC用于筛选免疫受体的潜在毒性的应用。 在一些方面，提供不表达HLA基因（例如HLA-A）的iPSC和从其分化的细胞。

公开(公告)号：US20160096902A1

公开(公告)日：2016-04-07

申请号：US14893223

申请日：2014-05-23

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Bipulendu JENA ,  Harjeet SINGH ,  David RUSHWORTH

IPC分类号： C07K16/42 ,  G01N33/566

CPC分类号： C07K16/4208 ,  C07K14/70503 ,  C07K14/70517 ,  C07K16/2803 ,  C07K16/4283 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/31 ,  C07K2319/33 ,  C12N5/0636 ,  C12N2510/00 ,  G01N33/566

摘要： Provided are monoclonal antibodies that detect CD 19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.

摘要翻译： 提供检测CD 19 CAR修饰的免疫细胞和CAR修饰的免疫细胞的单克隆抗体，而不管其靶向的肿瘤相关抗原。 使用这些功能性单克隆抗体的方法包括但不限于CAR修饰的免疫细胞的检测，定量，活化和选择性增殖。

公开(公告)号：US20220062396A1

公开(公告)日：2022-03-03

申请号：US17223597

申请日：2021-04-06

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  C07K14/725 ,  A61P37/00 ,  A61K35/17 ,  C07K14/54 ,  C07K14/705 ,  C07K16/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20170224798A1

公开(公告)日：2017-08-10

申请号：US15434595

申请日：2017-02-16

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K2039/505 ,  A61K2039/5158 ,  A61P37/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/30 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  Y02A50/411 ,  Y02A50/467

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20200085929A1

公开(公告)日：2020-03-19

申请号：US16543980

申请日：2019-08-19

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  A61P37/00 ,  C07K14/725 ,  A61K35/17 ,  C07K14/54 ,  C07K14/705 ,  C07K16/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20180265595A1

公开(公告)日：2018-09-20

申请号：US15912265

申请日：2018-03-05

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Bipulendu JENA ,  Sourindra MAITI ,  Harjeet SINGH ,  David RUSHWORTH

IPC分类号： C07K16/42 ,  C07K14/705 ,  C07K16/28 ,  G01N33/566 ,  C12N5/0783

CPC分类号： C07K16/4208 ,  C07K14/70503 ,  C07K14/70517 ,  C07K16/2803 ,  C07K16/4283 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/31 ,  C07K2319/33 ,  C12N5/0636 ,  C12N2510/00 ,  G01N33/566

摘要： Provided are monoclonal antibodies that detect CD19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.